Letter to the Editor
Copyright ©The Author(s) 2024.
World J Gastrointest Oncol. Dec 15, 2024; 16(12): 4766-4769
Published online Dec 15, 2024. doi: 10.4251/wjgo.v16.i12.4766
Table 1 Summary of meta-analysis key findings
Outcome
Number of studies
Main results (HR/OR, 95%CI)
Conclusions and ranking (P value)
OS41 (9 RCTs, 32 cohorts)HAIC + Lenv + A: HR = 0.12 (0.03-0.57) HAIC + A: HR = 0.21 (0.07-0.67) HAIC + Lenv: HR = 0.29 (0.11-0.74) HAIC + Sora: HR = 0.52 (0.33-0.81)HAIC + Lenv + A showed the best OS (P value: 0.94), followed by HAIC + A (P value: 0.85)
PFS30 (9 RCTs, 21 cohorts)HAIC + A: HR = 0.25 (0.08-0.77) HAIC + TACE: HR = 0.32 (0.14-0.75) HAIC: HR = 0.51 (0.33-0.78)HAIC + A had the most favorable PFS outcomes (P value: 0.79)
CR35 (8 RCTs, 27 cohorts)HAIC + Sora: OR = 7.62 (2.55-22.77) HAIC: OR = 2.86 (1.37-5.98)HAIC + Sora showed the best CR outcomes (P value: 0.86)
PR35 (8 RCTs, 27 cohorts)HAIC + TACE + S-1: OR = 13.29 (3.63-48.61) HAIC + Lenv: OR = 8.37 (4.32-16.23)HAIC + TACE + S-1 had the best PR outcomes (P value: 0.90), followed by HAIC + Lenv (P value: 0.79)
ORR35 (8 RCTs, 27 cohorts)HAIC + TACE + S-1: OR = 17.88 (2.22-143.80) HAIC + Lenv: OR = 13.92 (3.25-59.60)HAIC + TACE + S-1 showed the best ORR outcomes (P value: 0.79)
DCR35 (8 RCTs, 27 cohorts)HAIC + TACE + S-1: OR = 8.52 (1.56-46.49) HAIC + PD-1: OR = 7.26 (1.97-26.84)HAIC + TACE + S-1 had the best DCR outcomes (P value: 0.88)
Any grade AEs12 (4 RCTs, 12 cohorts)HAIC: OR = 0.48 (0.25-0.92) HAIC + Lenv: OR = 0.19 (0.05-0.72)HAIC showed the lowest incidence of any grade AEs (P value: 0.85)
Grade 3-4 AEs16 (5 RCTs, 11 cohorts)HAIC + Sora: OR = 0.26 (0.07-0.97) HAIC + Lenv: OR = 0.65 (0.12-3.43)HAIC demonstrated lower trends of grade 3-4 AEs than HAIC + Sora and TACE
A: Anti-angiogenic agent; AEs: Adverse events; CR: Complete response; DCR: Disease control rate; HAIC: Hepatic arterial infusion chemotherapy; HR: Hazard ratio; Lenv: Lenvatinib; OR: Odds ratio; ORR: Objective response rate; OS: Overall survival; PD-1: Programmed death 1; PFS: Progression-free survival; PR: Partial response; RCT: Randomized controlled trial; S-1: Oral fluoropyrimidine (composite preparation of 5-FU prodrug); Sora: Sorafenib; TACE: Transarterial chemoembolization.